News & Updates

Secukinumab may facilitate partial erosion repair and prevent enthesiophyte progression in patients with psoriatic arthritis (PsA), according to a phase IV randomized clinical trial (RCT).

Individuals with more components of cardiovascular–kidney–metabolic (CKM) syndrome, as defined by the American Heart Association, are at increased risks of all-cause mortality, cardiovascular disease (CVD) mortality, and end-stage kidney disease (ESKD), suggests a study.